JP2018501261A - Ｒａｓ阻害インデニルアセトアミド化合物、組成物、およびその使用 - Google Patents

Ｒａｓ阻害インデニルアセトアミド化合物、組成物、およびその使用 Download PDF

Info

Publication number
JP2018501261A
JP2018501261A JP2017533503A JP2017533503A JP2018501261A JP 2018501261 A JP2018501261 A JP 2018501261A JP 2017533503 A JP2017533503 A JP 2017533503A JP 2017533503 A JP2017533503 A JP 2017533503A JP 2018501261 A JP2018501261 A JP 2018501261A
Authority
JP
Japan
Prior art keywords
methyl
acetamide
inden
hydroxy
dimethoxybenzylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017533503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501261A5 (enExample
Inventor
ゲイリー エー． ピアッザ，
ゲイリー エー． ピアッザ，
シー チェン，
シー チェン，
アダム ビー． キートン，
アダム ビー． キートン，
Original Assignee
エーディーティー ファーマシューティカルズ，エルエルシー
エーディーティー ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーディーティー ファーマシューティカルズ，エルエルシー, エーディーティー ファーマシューティカルズ，エルエルシー filed Critical エーディーティー ファーマシューティカルズ，エルエルシー
Publication of JP2018501261A publication Critical patent/JP2018501261A/ja
Publication of JP2018501261A5 publication Critical patent/JP2018501261A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017533503A 2014-12-16 2014-12-16 Ｒａｓ阻害インデニルアセトアミド化合物、組成物、およびその使用 Pending JP2018501261A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/070511 WO2016099452A1 (en) 2014-12-16 2014-12-16 Ras-inhibiting indenyl acetamide compounds, compositions, and uses

Publications (2)

Publication Number Publication Date
JP2018501261A true JP2018501261A (ja) 2018-01-18
JP2018501261A5 JP2018501261A5 (enExample) 2018-03-01

Family

ID=56127110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533503A Pending JP2018501261A (ja) 2014-12-16 2014-12-16 Ｒａｓ阻害インデニルアセトアミド化合物、組成物、およびその使用

Country Status (5)

Country Link
US (1) US20170342021A1 (enExample)
EP (1) EP3233070A4 (enExample)
JP (1) JP2018501261A (enExample)
CN (1) CN107530303A (enExample)
WO (1) WO2016099452A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020079307A (ja) * 2014-12-16 2020-05-28 エーディーティー ファーマシューティカルズ，エルエルシー インデニル化合物、医薬組成物、およびその医学的使用
US11680073B2 (en) 2018-04-26 2023-06-20 Adt Pharmaceuticals, Llc Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
EP3630089A4 (en) * 2017-05-24 2021-06-09 Ferro Therapeutics, Inc. PROCEDURE FOR CANCER THERAPY
AU2019229256A1 (en) 2018-02-28 2020-09-17 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514417A (ja) * 1996-06-13 2000-10-31 セル パスウェイズ インコーポレイテッド 置換ベンジリデンインデニルホルムアミド、アセタミドおよびプロピオンアミド
JP2007534702A (ja) * 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
JP2009522364A (ja) * 2006-01-04 2009-06-11 サザン リサーチ インスティテュート スリンダクの誘導体類、その使用及びその調製

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514417A (ja) * 1996-06-13 2000-10-31 セル パスウェイズ インコーポレイテッド 置換ベンジリデンインデニルホルムアミド、アセタミドおよびプロピオンアミド
JP2007534702A (ja) * 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
JP2009522364A (ja) * 2006-01-04 2009-06-11 サザン リサーチ インスティテュート スリンダクの誘導体類、その使用及びその調製

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, JPN6018034078, 2009, pages 1959 - 1971, ISSN: 0003870785 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, JPN6018034059, 2012, pages 17 - 29, ISSN: 0004008735 *
REGISTRY(STN)[ONLINE], JPN7018002966, ISSN: 0004008736 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020079307A (ja) * 2014-12-16 2020-05-28 エーディーティー ファーマシューティカルズ，エルエルシー インデニル化合物、医薬組成物、およびその医学的使用
US11407727B2 (en) 2014-12-16 2022-08-09 Adt Pharmaceuticals, Llc Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US12479813B2 (en) 2014-12-16 2025-11-25 Adt Pharmaceuticals, Llc Method of therapeutically treating cancer
US11680073B2 (en) 2018-04-26 2023-06-20 Adt Pharmaceuticals, Llc Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses

Also Published As

Publication number Publication date
EP3233070A1 (en) 2017-10-25
EP3233070A4 (en) 2018-08-08
US20170342021A1 (en) 2017-11-30
CN107530303A (zh) 2018-01-02
WO2016099452A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
US9931315B2 (en) Method of selectively inhibiting Ras-mediated tumor growth in humans
JP6698089B2 (ja) インデニル化合物、医薬組成物、およびその医学的使用
JP2018501261A (ja) Ｒａｓ阻害インデニルアセトアミド化合物、組成物、およびその使用
WO2017106520A1 (en) Compounds, compositions and methods of treating cancer
US20210261572A1 (en) Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses
HK1244205A1 (en) Method of treating or preventing ras-mediated diseases
HK1244205B (en) Method of treating or preventing ras-mediated diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180903

A25B Request for examination refused [due to the absence of examination request for another application deemed to be identical]

Free format text: JAPANESE INTERMEDIATE CODE: A2522

Effective date: 20180903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190401